Baader Bank Reiterates “€7.80” Price Target for Encavis (CAP)

Baader Bank set a €7.80 ($9.63) price target on Encavis (ETR:CAP) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Oddo Bhf set a €7.15 ($8.83) target price on shares of Encavis and gave the stock a buy rating in a report on Friday, February 23rd. DZ Bank reaffirmed a buy rating on shares of Encavis in a report on Wednesday, January 17th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus target price of €7.99 ($9.86).

Shares of Encavis stock opened at €6.57 ($8.11) on Thursday. Encavis has a fifty-two week low of €5.85 ($7.22) and a fifty-two week high of €7.15 ($8.83).

TRADEMARK VIOLATION WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3342428/baader-bank-reiterates-7-80-price-target-for-encavis-cap.html.

Encavis Company Profile

Encavis AG, formerly Capital Stage AG, is a Germany-based producer of electricity from renewable energy sources. The Company invests in solar and wind parks, which it also operates. The Company divides its activities into four segments: Solar Parks, which is engaged in acquisition and operation of ground mounted photovoltaic (PV) parks; Wind Parks, engaged in acquisition and operation of onshore wind parks; Institutional Clients, which, through Encavis Asset Management AG, offers customized portfolios or fund solutions for investments in renewable energies, and Technical Services, responsible for technical operation and maintenance of PV parks.

Analyst Recommendations for Encavis (ETR:CAP)

Receive News & Ratings for Encavis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encavis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Expect PotlatchDeltic  to Post $0.67 EPS
Zacks: Brokerages Expect PotlatchDeltic to Post $0.67 EPS
Zacks: Brokerages Expect BioCryst Pharmaceuticals  Will Announce Quarterly Sales of $10.20 Million
Zacks: Brokerages Expect BioCryst Pharmaceuticals Will Announce Quarterly Sales of $10.20 Million
Virtacoinplus  Price Up 175% Over Last Week
Virtacoinplus Price Up 175% Over Last Week
Sumokoin Tops One Day Trading Volume of $76,838.00
Sumokoin Tops One Day Trading Volume of $76,838.00
Entegris  Updates Q2 Earnings Guidance
Entegris Updates Q2 Earnings Guidance
PCM  Releases Quarterly  Earnings Results, Beats Estimates By $0.05 EPS
PCM Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS


© 2006-2018 Ticker Report. Google+.